| Tripelennamine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Tripelennamine | hsa00040 | Pentose and glucuronate interconversions | 4.00E-02 | 1 | P15121 | AKR1B1 | More | |
| Tripelennamine | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
| Tripelennamine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
| Tripelennamine | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
| Tripelennamine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Tripelennamine | hsa00790 | Folate biosynthesis | 2.02E-02 | 1 | P15121 | AKR1B1 | More | |
| Tripelennamine | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | |
| Tripelennamine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.00E-02 | 1 | P09211 | GSTP1 | More | |
| Tripelennamine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Tripelennamine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Tripelennamine | hsa02010 | ABC transporters | 2.17E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | |
| Tripelennamine | hsa03010 | Ribosome | 2.25E-04 | 5 | P40429, Q07020, P27635, P05386, P62249 | RPL13A, RPL18, RPL10, RPLP1, RPS16 | More | |
| Tripelennamine | hsa03013 | RNA transport | 3.98E-02 | 9 | P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | |
| Tripelennamine | hsa03020 | RNA polymerase | 4.40E-02 | 2 | P24928, P62487 | POLR2A, POLR2G | More | |
| Tripelennamine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
| Tripelennamine | hsa03320 | PPAR signaling pathway | 4.33E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | |
| Tripelennamine | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | |
| Tripelennamine | hsa04022 | cGMP-PKG signaling pathway | 2.55E-02 | 4 | P18848, Q8WYR1, P05141, P0DP24 | ATF4, PIK3R5, SLC25A5, CALM2 | More | |
| Tripelennamine | hsa04071 | Sphingolipid signaling pathway | 8.10E-04 | 7 | P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | |
| Tripelennamine | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Tripelennamine | hsa04114 | Oocyte meiosis | 6.23E-03 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | |
| Tripelennamine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Tripelennamine | hsa04146 | Peroxisome | 2.42E-02 | 5 | O43933, P56589, Q9UKG9, O75521, P33121 | PEX1, PEX3, CROT, ECI2, ACSL1 | More | |
| Tripelennamine | hsa04151 | PI3K-Akt signaling pathway | 7.39E-03 | 7 | P62753, O43521, P27348, Q8WYR1, P18848, O00141, Q6ZUJ8 | RPS6, BCL2L11, YWHAQ, PIK3R5, ATF4, SGK, PIK3AP1 | More | |
| Tripelennamine | hsa04210 | Apoptosis | 3.63E-02 | 3 | O75460, O43521, P18848 | ERN1, BCL2L11, ATF4 | More | |
| Tripelennamine | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | |
| Tripelennamine | hsa04217 | Necroptosis | 3.89E-04 | 9 | P01375, P48023, Q14765, P15104, P05141, P01584, P0C0S5, Q99878, Q9H444 | TNF, FASLG, STAT4, GLUL, SLC25A5, IL1B, H2AFZ, H2AC14, CHMP4B | More | |
| Tripelennamine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Tripelennamine | hsa04370 | VEGF signaling pathway | 3.06E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | |
| Tripelennamine | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 4.73E-02 | 3 | Q13873, Q02750, Q86SE9 | BMPR2, MAP2K1, PCGF5 | More | |
| Tripelennamine | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | |
| Tripelennamine | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Tripelennamine | hsa04613 | Neutrophil extracellular trap formation | 3.12E-05 | 21 | P11215, O60603, P05164, P08246, Q9UM07, Q13547, P04908, Q6FI13, Q93077, P58876, Q16778, O60814, P68431, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | ITGAM, TLR2, MPO, ELA2, PADI4, HDAC1, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, H2BC5, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | |
| Tripelennamine | hsa04650 | Natural killer cell mediated cytotoxicity | 5.56E-05 | 10 | P16298, P50591, P01375, P20963, Q02750, Q13241, P26718, P26717, Q14953, P26715 | PPP3CB, TNFSF10, TNF, CD247, MAP2K1, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Tripelennamine | hsa04657 | IL-17 signaling pathway | 4.27E-03 | 7 | O00463, Q16539, P19875, P14780, Q9UJX4, P80188, P01375 | TRAF5, MAPK14, CXCL2, MMP9, ANAPC5, LCN2, TNF | More | |
| Tripelennamine | hsa04668 | TNF signaling pathway | 2.67E-03 | 6 | P01375, P18848, P19875, P01584, P14780, P20333 | TNF, ATF4, CXCL2, IL1B, MMP9, TNFRSF1B | More | |
| Tripelennamine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
| Tripelennamine | hsa04720 | Long-term potentiation | 2.85E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
| Tripelennamine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Tripelennamine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Tripelennamine | hsa04914 | Progesterone-mediated oocyte maturation | 1.00E-02 | 4 | Q17RY0, Q9Y6D9, P51812, Q02750 | CPEB4, MAD1L1, RPS6KA3, MAP2K1 | More | |
| Tripelennamine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Tripelennamine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
| Tripelennamine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Tripelennamine | hsa04932 | Non-alcoholic fatty liver disease | 1.52E-05 | 10 | P01375, P49841, O43521, P18848, P48023, O75460, P01584, P13073, Q16718, O14521 | TNF, GSK3B, BCL2L11, ATF4, FASLG, ERN1, IL1B, COX4I1, NDUFA5, SDHD | More | |
| Tripelennamine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Tripelennamine | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Tripelennamine | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Tripelennamine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Tripelennamine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | |
| Tripelennamine | hsa05010 | Alzheimer disease | 2.78E-02 | 6 | P13073, O75460, P0DP24, P01584, P18848, P05141 | COX4I1, ERN1, CALM2, IL1B, ATF4, SLC25A5 | More | |
| Tripelennamine | hsa05012 | Parkinson disease | 3.89E-02 | 5 | P13073, P05141, O75460, P18848, P0DP24 | COX4I1, SLC25A5, ERN1, ATF4, CALM2 | More | |
| Tripelennamine | hsa05016 | Huntington disease | 4.87E-02 | 5 | P13073, P24928, P62487, P05141, O75460 | COX4I1, POLR2A, POLR2G, SLC25A5, ERN1 | More | |
| Tripelennamine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | |
| Tripelennamine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 6.94E-04 | 13 | P49841, Q16718, O14521, P13073, O75460, P18848, Q13561, P05141, P20333, Q16539, P01584, Q08752, P0DP24 | GSK3B, NDUFA5, SDHD, COX4I1, ERN1, ATF4, DCTN2, SLC25A5, TNFRSF1B, MAPK14, IL1B, PPID, CALM2 | More | |
| Tripelennamine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Tripelennamine | hsa05034 | Alcoholism | 2.10E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Tripelennamine | hsa05100 | Bacterial invasion of epithelial cells | 2.85E-02 | 3 | Q14141, Q05397, Q96JJ3 | SEPT6, PTK2, ELMO2 | More | |
| Tripelennamine | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | |
| Tripelennamine | hsa05135 | Yersinia infection | 3.29E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | |
| Tripelennamine | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | |
| Tripelennamine | hsa05144 | Malaria | 1.44E-03 | 5 | P69905, P68871, P01375, P35443, P26718 | HBA2, HBB, TNF, THBS4, KLRK1 | More | |
| Tripelennamine | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Tripelennamine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Tripelennamine | hsa05171 | Coronavirus disease - COVID-19 | 3.87E-04 | 5 | P62249, P40429, P27635, Q07020, P05386 | RPS16, RPL13A, RPL10, RPL18, RPLP1 | More | |
| Tripelennamine | hsa05202 | Transcriptional misregulation in cancer | 1.62E-03 | 15 | Q15532, P41732, P14780, P27930, P14923, Q16548, P11215, Q13077, O15550, P35226, P05164, P08246, Q13547, P12980, P24522 | SS18, TSPAN7, MMP9, IL1R2, JUP, BCL2A1, ITGAM, TRAF1, UTX, BMI1, MPO, ELA2, HDAC1, LYL1, GADD45A | More | |
| Tripelennamine | hsa05203 | Viral carcinogenesis | 6.44E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
| Tripelennamine | hsa05204 | Chemical carcinogenesis | 4.00E-02 | 1 | P09211 | GSTP1 | More | |
| Tripelennamine | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
| Tripelennamine | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Tripelennamine | hsa05322 | Systemic lupus erythematosus | 1.18E-02 | 3 | P58876, Q16778, O60814 | H2BC5, HIST2H2BE, H2BC12 | More | |
| Tripelennamine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Tripelennamine | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
| Tripelennamine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |
| Tripelennamine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | |
